报名：第三届类器官技术创新及应用进展网络会议

Core Viewpoint - Organoid technology is a revolutionary breakthrough in life sciences, showing great potential in drug development, disease mechanism analysis, and personalized medicine, with the FDA planning to phase out animal testing by 2025 and positioning organoids as a core tool for drug safety evaluation [1] Group 1: Challenges in Organoid Technology - Insufficient technological maturity remains the primary challenge, with over 60% necrosis rate in long-term cultures due to the lack of vascular networks and immune microenvironments [1] - The absence of standardization is a significant issue, leading to substantial batch-to-batch heterogeneity and a lack of international standards for evaluating morphological, functional, and molecular characteristics [1] - Low automation equipment penetration rates contribute to human operational errors and limit high-throughput capabilities, hindering clinical application promotion [1] Group 2: Upcoming Conference - The "Third Organoid Technology Innovation and Application Progress Online Conference" will be held on July 15-16, focusing on "Technical Breakthroughs - Standard Co-construction - Ecological Collaboration" [2] - The conference will feature four thematic sessions: "Progress in Organoid Simulation Technology," "Clinical Applications and Transformation of Organoids," "Organoid Model Construction and Drug Development," and "Standardization and Automation of Organoids" [2] Group 3: Conference Agenda Highlights - On July 15, sessions will cover topics such as bio 3D printing and high-throughput genetic screening technologies in organoids, with notable speakers from Tsinghua University and Shanghai University [3][4] - The second day will focus on organoid model construction and drug development, including discussions on animal alternatives and optimization methods for 3D organoid culture [4]